ライフサイエンスコーパス: cell therapy

1 echnical challenges to developing successful cell therapy.

2 eta, suggesting a novel approach to adoptive cell therapy.

3 rucial role of cell dose in the responses to cell therapy.

4 ies such as checkpoint blockade and adoptive cell therapy.

5 peutic benefits associated with CD34(+) stem cell therapy.

6 of cardiac functions similar to cardiac stem cell therapy.

7 orably condition CD8(+) T cells for adoptive cell therapy.

8 eceived chimeric antigen receptor-modified T cell therapy.

9 urs in many autoimmune patients after anti-B cell therapy.

10 s in vascular research, drug development and cell therapy.

11 a modest benefit in patients receiving stem cell therapy.

12 CRS and other adverse events following CAR T-cell therapy.

13 nciple for therapeutic cloning combined with cell therapy.

14 ial translational significance in adoptive T-cell therapy.

15 for 7.5 months after the initiation of CAR T-cell therapy.

16 erentiation of grafted cells during neonatal cell therapy.

17 studies were safety and tolerability of this cell therapy.

18 showed significant functional improvement by cell therapy.

19 s as an alternative to hepatocytes for liver cell therapy.

20 s contribute to the limited efficacy of stem cell therapy.

21 create cells that are ideal for personalized cell therapy.

22 refractory MLL-B-ALL who receive CD19 CAR-T-cell therapy.

23 derived neural cells in disease modeling and cell therapy.

24 on who would likely benefit from adoptive NK-cell therapy.

25 cytes (CMs) are a promising tool for cardiac cell therapy.

26 etes also impairs reparative responses after cell therapy.

27 onjugate vaccines, bispecific antibodies and cell therapy.

28 anslatable genetic modification strategy for cell therapy.

29 umulation in tumors in a model of adoptive T cell therapy.

30 nts with ischemic heart disease treated with cell therapy.

31 an important step in clinical development of cell therapy.

32 uses on their potential role as new tool for cell therapy.

33 a practical approach to improving SHED-based cell therapy.

34 cently, to investigations of stem/progenitor cell therapy.

35 ransduced, making them viable candidates for cell therapy.

36 ential step to obtain effective products for cell therapy.

37 n of more effective protocols for adoptive T-cell therapy.

38 te safer application of effective CD19 CAR T-cell therapy.

39 oactive infusions a median of 5 days after T cell therapy.

40 al approach for restoring hair cells is stem cell therapy.

41 t of PIRI including CLI with or without stem cell therapy.

42 through genetics and the development of stem-cell therapy.

43 e after chimeric antigen receptor-modified T cell therapy.

44 vival and rejection in preclinical models of cell therapy.

45 l cancer after tumor-infiltrating adoptive T cell therapy.

46 nsion, rest pain, and walking capacity after cell therapy.

47 ticular in organ transplantation and in stem cell therapy.

48 it expected therapeutic benefits of adoptive cell therapy.

49 enome engineering to enhance next-generation cell therapies.

50 for the development of future clinical stem cell therapies.

51 is easily scalable in contrast to adoptive T-cell therapies.

52 lines, which would compromise their use for cell therapies.

53 J-64041757), and chimeric antigen receptor T-cell therapies.

54 elium holds promise for potential autologous cell therapies.

55 uromodulation and experimental gene and stem cell therapies.

56 ent advances opens the way for improved MPhi cell therapies.

57 trials and inform the design of future CAR T cell therapies.

58 strategy for improving the potency of CAR T cell therapies.

59 pporting the feasibility of autologous liver cell therapies.

60 ing of optic neuropathies and development of cell therapies.

61 can potentially be used in autologous liver cell therapies.

62 ckpoint inhibitors, vaccines, and adoptive T-cell therapies.

63 f soluble mediators in the context of immune cell therapies.

64 ll receptor targets in innovative adoptive T cell therapies.

65 development of stem-cell-based engineered T cell therapies.

66 ation design of receptors used in adoptive T cell therapies.

67 offers a promising strategy for making stem cell therapy a clinical reality.

68 Despite the promising efficacy of adoptive cell therapies (ACT) in melanoma, complete response rate

69 Adoptive cell therapy (ACT) trials to date have focused on transf

70 Adoptive T cell therapy (ACT) with antitumor CTL is a promising and

71 from PD-1(+) TILs can be used in adoptive T-cell therapy (ACT).

72 epletion enhances the efficacy of adoptive T cell therapy (ACT).

73 Discovery of effective cell therapies against cancer can be accelerated by the

74 lations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval

75 fforts to improve the efficacy of adoptive T-cell therapies and immune checkpoint therapies in myelog

76 bes enable quantitative in vivo detection of cell therapies and inflammatory cells.

77 e approaches to enhance the efficacy of stem cell therapies and to overcome issues with cell therapy

78 New avenues of exploration include cardiac cell therapy and cellular reprogramming targeting cell d

79 e reported weighted mean differences between cell therapy and control groups.

80 tes (hPSC-CMs) constrains their potential in cell therapy and drug testing.

81 It has also pioneered the concepts of stem cell therapy and immunotherapy as a tool against cancer.

82 nterfere with immune cells used for adoptive cell therapy and may limit expected therapeutic benefits

83 s that potentially limit mutation-specific T-cell therapy and may require high-avidity TCRs that are

84 SCs) are among the major stem cells used for cell therapy and regenerative medicine.

85 T cells enhances the efficacy of adoptive T cell therapy and suggests a new therapeutic strategy for

86 pecific intracellular antigens without using cell therapy and suggests that epitope spreading could c

87 al trials, clarifying the perception of stem cell therapy and the risks of bone marrow harvest, and d

88 el substrates for cell culture applications, cell therapy and tissue engineering.

89 itive ion channels in the heart (via gene or cell therapy) and illumination of the cardiac surfaces (

90 erapeutic success in the field of hMSC-based cell therapy, and an optimal approach for hMSC-based cel

91 TCR/CD3, as a cornerstone compound in anti-T-cell therapy, and anti-TNF-alpha, as the most prominent

92 nsitive sensing, disease diagnostics, cancer cell therapy, and molecular computers.

93 logic feature can be exploited in allogeneic cell therapy, and the recognition of "missing-self" on t

94 toxic effector functions of TCM for adoptive cell therapy applications.

95 reg cell-mediated suppression and a new Treg cell therapy approach.

96 An issue with cell therapy approaches to restore dystrophin expression

97 a source of cells for tissue engineering and cell therapy approaches.

98 for the development of successful autologous cell therapy approaches.

99 T-cell therapies are a promising approach for treating MM,

100 r, the underlying mechanisms of iPSC-derived cell therapy are still unclear, and limited engraftment

101 ing results for HSCT and mesenchymal stromal cell therapy as alternatives to systemic therapies and a

102 illustrate the potential use of SLAMF7-CAR T-cell therapy as an effective treatment against multiple

103 the potential clinical benefit of adoptive T-cell therapy (ATCT) of CMV phosphoprotein 65 (pp65)-spec

104 Adoptive T cell therapy (ATT) can achieve regression of large tumor

105 ajority of T cells suboptimal for adoptive T-cell therapy (ATT).

106 of the AML patients receiving adoptive NK-92 cell therapy block anti-leukemia cytotoxicity of NK-92 c

107 Emerging technologies--such as stem cell therapy, bone anabolic agents, genetic approaches,

108 The disease is a potential target for stem cell therapy but success is likely to be limited by the

109 ciated self-antigens that are amenable for T-cell therapy, but also allows TCR targeting of the cance

110 molysis bullosa treated with allogeneic stem cell therapy, but with little success.

111 nt cells may contribute to the efficacy of T-cell therapy by maintaining effector function and promot

112 Cell therapies can be also delivered intratumorally, inc

113 NK cell therapy can be further improved by optimal donor se

114 Thus, application of optogenetics in cell therapy can link transplantation, animal behavior a

115 nized early and treated with targeted plasma cell therapy, can be managed very effectively.

116 nic stimulation in tumors and after adoptive cell therapy, CD8 TCR signaling and Nur77GFP induction i

117 Application of miR-146b combined with stem cell therapy could enhance regeneration of cartilaginous

118 Umbilical cord-mesenchymal stem/stromal cell therapy decreased nicotinamide adenine dinucleotide

119 The efficacy of cardiac cell therapy depends on the integration of existing and

120 nts with fistulizing CD, mesenchymal stromal cell therapy deposits MSCs locally, into fistulizing tra

121 trategies to increase PCs and exogenous stem cell therapies designed to improve regenerative capacity

122 We found that anti-B cell therapy did not alter the frequencies of autoreacti

123 therapeutic agents as well as vaccine and T-cell therapies directed at mesothelin are undergoing cli

124 were randomly assigned to receive autologous cell therapy (endothelial cells, n = 4) or control treat

125 Cells therapies, engineered to secrete replacement prote

126 cted organ damage and deaths following CAR T-cell therapy first highlighted the possible dangers of t

127 nical ventilation a median of 6 days after T cell therapy; five met criteria for acute respiratory di

128 Assessing the retention of cell therapies following implantation is vital and often

129 ance the efficacy of vaccines and adoptive T cell therapies for cancer and infectious diseases or, co

130 nalyses have recently arisen in the field of cell therapies for cardiovascular repair and regeneratio

131 espite encouraging preliminary results, stem cell therapies for patients with CHD should only be cons

132 o Food and Drug Administration-approved stem cell therapies for retinal disease exist.

133 nt clinical translation of neural progenitor cell therapy for ALS.

134 success of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies represents a paradi

135 Recent advances in T-cell therapy for cancer, viral infections, and autoimmun

136 Conclusions and Relevance: Although stem cell therapy for cardiovascular disease is not yet ready

137 be used to advance development of adoptive T-cell therapy for HCC.

138 evaluating safety and efficacy of autologous cell therapy for intractable peripheral arterial disease

139 Autologous and allogeneic cell therapy for ischemic heart disease show a similar i

140 the effectiveness of cardiac stem/progenitor cell therapy for ischemic heart disease.

141 In a mouse model of adoptive T cell therapy for melanoma, Runx3-deficient CD8(+) tumour

142 t challenge for the continued development of cell therapy for Parkinson's disease (PD) is the establi

143 rategies to augment the feasibility of CAR T-cell therapy for patients with AML.

144 rome occurred in 46% of patients following T cell therapy for relapsed/refractory acute lymphoblastic

145 ss with chimeric antigen receptor-modified T cell therapy for relapsed/refractory acute lymphoblastic

146 system development and serve as a potential cell therapy for SCI.

147 potential as an autologous, multifunctional cell therapy for stroke, which is the primary cause of l

148 ed CD40L, and the potential for its use in T-cell therapy for X-HIGM syndrome.

149 bronchoalveolar lavage were reduced in both cell therapy groups, despite a reduction in bronchoalveo

150 s the gold standard treatment modality, stem cell therapy has been gaining ground as a complimentary

151 c antigen receptor (CAR)-modified adoptive T-cell therapy has been successfully applied to the treatm

152 regenerative medicine mediated by adult stem cell therapy has gathered momentum fueled by tantalizing

153 RATIONALE: Stem cell therapy has increased the therapeutic armamentarium

154 Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in clinical

155 Stem cell therapy has recently emerged as a promising method

156 Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy for the manageme

157 Recently, adoptive T-cell therapy has shown salvage responses in multiple ref

158 Adoptive T cell therapy has shown significant clinical success for

159 Cardiac stem cell therapy has shown very promising potential to repai

160 y no longer be guaranteed because autologous cell therapy has the potential to modify the natural his

161 Treatment of cancer patients by adoptive T cell therapy has yielded promising results.

162 Adoptive T cell therapies have achieved significant clinical respon

163 Current progenitor cell therapies have only modest efficacy, which has limi

164 Gene and cell therapies have the potential to prevent, halt, or r

165 ansplantation (HSCT) and mesenchymal stromal cell therapy have been proposed for patients with refrac

166 m cell therapies and to overcome issues with cell therapy have been used with varied success.

167 marrow transplantation and mesenchymal stem cell therapy, have entered into early clinical trials.

168 splanting autologous beta-cells for diabetes cell therapy, highlighting the unique advantages and cha

169 Although adoptive T-cell therapy holds promise for the treatment of many can

170 ne marrow by flow cytometry after CD19 CAR-T-cell therapy; however, within 1 month of CAR-T-cell infu

171 tions for the development of effective CAR T cell therapies in cancer patients.

172 he safety and efficacy of different types of cell therapies in patients with ischemic stroke.

173 ed catheter-directed delivery of endothelial cell therapy in a porcine model of cirrhosis for liver r

174 itioned medium (CM-MSC) as an alternative to cell therapy in an antigen-induced model of arthritis (A

175 ndation of cellular engineering for adoptive cell therapy in cancer and other diseases.

176 ication of chimeric antigen receptor (CAR) T cell therapy in cancers.

177 SC-based strategies for disease modeling and cell therapy in CNS disorders.

178 ys for beta-cell generation is essential for cell therapy in diabetes.

179 rolled preclinical trials of unmodified stem cell therapy in large animal models of myocardial ischem

180 melanoma antigens before and after adoptive cell therapy in melanoma patients, we observe a greater

181 ch are of the greatest interest for adoptive cell therapy in patients with cancer.

182 riers to the clinical implementation of stem cell therapy in patients with cardiovascular disease and

183 rs facing the routine implementation of stem cell therapy in patients with cardiovascular disease is

184 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukem

185 d transendocardial injection of ixmyelocel-T cell therapy in patients with heart failure and reduced

186 ently being examined in clinical trials as T cell therapy in patients with inflammatory bowel disease

187 cells (MSC) have become a promising tool for cell therapy in regenerative medicine.

188 n approach for improving mesenchymal stromal cell therapy in scleroderma and other diseases.

189 vices may improve the effectiveness of CAR T cell therapy in solid tumors and help protect against th

190 e considered during the design of adoptive T cell therapies, including use of engineered T cells.

191 We review key achievements in T-cell therapy, including the use of recombinant immune re

192 replacement, autologous and allogeneic stem cell therapy, innovations in cancer biology, revertant m

193 well as the unaddressed integration of CAR T-cell therapy into conventional anticancer treatments.

194 Future peripheral artery disease cell therapy investigational trial design may be informe

195 The design, and manufacturing, of T cell therapies is not standardized and is performed most

196 ABSTRACT: Autologous cardiac progenitor cell therapy is a promising alternative approach to curr

197 CD4(+)CD25(+)Foxp3(+) regulatory T (Treg) cell therapy is a promising approach for the treatment o

198 Importance: Stem cell therapy is a promising treatment strategy for patie

199 Chimeric antigen receptor (CAR) T-cell therapy is an emerging immunotherapy against severa

200 Refinement of this T-cell therapy is crucial to improve the frequency of clin

201 An innovative microneedle (MN)-based cell therapy is developed for glucose-responsive regulat

202 Adoptive immune cell therapy is emerging as a promising immunotherapy fo

203 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-c

204 y, the general application of current CAR-T--cell therapy is limited by serious treatment-related tox

205 in solid tumors, the full potential of CAR T cell therapy is limited by the availability of cell surf

206 Despite important achievements to date, stem cell therapy is not yet ready for routine clinical imple

207 small-scale studies have suggested that stem-cell therapy is safe and effective in patients with live

208 nd beta-cells is crucial for developing stem cell therapies, islet regeneration strategies, and thera

209 when generating T-cell lines for adoptive T-cell therapy, it avoids the loss of those clones, which

210 r drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-med

211 se strategies could help overcome unresolved cell therapy manufacturing challenges and complement fra

212 boratories, clinical diagnostics assays, and cell therapy manufacturing.

213 The recognition that cell therapy may be cardioprotective, and not just regen

214 able strategy to improve anti-tumor adoptive cell therapy may be to engineer tumor-restricted T cells

215 al studies; it suggests that the benefits of cell therapy may be underestimated or even overlooked if

216 tion of fetal neural precursors suggest that cell therapy may offer a cure for this devastating neuro

217 We conclude that anti-B cell therapy may provide a temporary dampening of autoim

218 of low survivability in current cardiac stem cell therapies, mechanical and metabolic, were explored.

219 of regenerating appropriate connections for cell therapy.Midbrain dopaminergic neurons (mDAs) in the

220 ods to define dose and pharmacokinetics of T cell therapies need to be developed.

221 progenitor cells (hBTSCs) are being used for cell therapies of patients with liver cirrhosis.

222 that FRbeta is a promising target for CAR T-cell therapy of AML, which may be augmented by combinati

223 Adoptive cell therapy of chronic lymphocytic leukemia (CLL) with

224 g cells (ECFCs) are promising candidates for cell therapy of ischemic diseases, as less than 10% of p

225 tention and animal survival for in vivo stem cell therapy of myocardial infarction.

226 romoting cell engraftment and thus improving cell therapy of the infarcted myocardium.

227 BACKGROUND & AIMS: Cell therapy offers the potential to treat gastrointesti

228 ed with chimeric antigen receptor-modified T cell therapy on a phase I/IIa clinical trial.

229 Remarkably, efficacy of cell therapy on all end points was no longer significant

230 ndividual patient data reported no effect of cell therapy on left ventricular function or clinical ou

231 No effect of cell therapy on major adverse cardiac and cerebrovascula

232 Stem cell therapy once held promise for generating large quan

233 cise changes to gene expression for gene and cell therapies or fundamental studies of gene function.

234 Intraportal delivery of endothelial cell therapy or saline was technically successful in all

235 The Pulmonary Hypertension and Angiogenic Cell Therapy (PHACeT) trial was a phase 1, dose-escalati

236 Mechanisms of regulatory B cells and their cell therapy potential are important to decipher in expe

237 cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immune system, a

238 sed as a reference for characterizing future cell therapy products destined to treat endothelial dysf

239 shelf, genetically enhanced, histocompatible cell therapy products.

240 Undoubtedly, as insulin producing stem cell therapies progress, a transplant site that is retri

241 Stem cell therapy provides immense hope for regenerating the

242 ll randomized controlled trials) showed that cell therapy reduced the risk of amputation by 37%, impr

243 sruption of inhibitory checkpoints and CAR T cell therapy remains incompletely explored.

244 int blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immun

245 Stem cell therapy represents a promising strategy in regenera

246 Further development of engineered T cell therapies requires advances in immunology, syntheti

247 Development of cell therapy requires a better understanding of the sign

248 However, T cell therapy requires efficient generation of the select

249 Further development of T cell therapy requires improved strategies to select effe

250 y enrolled in the CCTRN TIME (Cardiovascular Cell Therapy Research Network Timing in Myocardial Infar

251 t protein inhibition, vaccines, and adoptive cell therapy seem to activate more specific T cells that

252 Swine treated with endothelial cell therapy showed mean levels of surrogate markers of

253 anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractor

254 Cell therapy significantly increased ankle brachial inde

255 SCs) are ideal cell sources for personalized cell therapies since they can be expanded to generate la

256 fusion and nuclear reprogramming may aid in cell therapy strategies for skeletal muscle diseases.

257 ring these cells ex vivo and using them in T-cell therapy strategies.

258 to the AML-NK dysfunction and a potential NK cell therapy strategy.

259 eir families and discussing participation in cell therapy studies are described, including participat

260 Informed consent for cell therapy studies in patients with stroke requires le

261 o the modest functional benefits observed in cell-therapy studies by regulating the amount of contrac

262 of our knowledge, ixCELL-DCM is the largest cell therapy study done in patients with heart failure s

263 her alone or used in, combination with other cell therapies (such as hematopoietic stem cells or bone

264 Some early-phase trials of cell therapies suggest acceptable safety profiles.

265 al framework for the development of targeted cell therapies that can be customized to any clinical ap

266 ssociated with low levels of autoimmunity to cell therapies that can induce damaging cross-reactivity

267 CCs are a novel cell therapy that improves on combinatorial cell approac

268 wever, it remains largely unknown how anti-B cell therapy thwarts autoimmunity in these pathologies.

269 anslational therapeutic strategies including cell therapy, tissue engineering, and regenerative medic

270 e safety and efficacy of mesenchymal stromal cell therapies to allow the translation of this research

271 However, gene, protein and cell therapies to increase microvascularization have not

272 sequently, TECs are an attractive target for cell therapies to restore effective immune system functi

273 ategies to improve and tailor Treg cells for cell therapy to induce transplantation tolerance are hig

274 lecules may expand the scope of engineered T-cell therapy to solid tumors, as well as indications bey

275 used human TR1 cells, currently employed for cell therapy, to confirm our results.

276 used to enhance vaccine efficacy or adoptive cell therapy treatments that target cancer.

277 cardial Infarction Evaluation) was the first cell therapy trial sufficiently powered to determine if

278 s for recruitment of patients with stroke in cell therapy trials is complex and requires extensive di

279 This study summarizes the use of adoptive cell therapy, tumor vaccines, immune checkpoint inhibito

280 hematologic complete remission (CR) after T-cell therapy, upon emergence of (p190)BCR-ABL-specific T

281 Importantly, cell therapies using IRE1alpha-expressing BMPCs or direc

282 safety and efficacy of an adoptive CD4(+) T-cell therapy using an MHC class II-restricted, HLA-DPB1*

283 RATIONALE: Autologous stem cell therapy using human c-Kit(+) cardiac progenitor cel

284 rapy, and an optimal approach for hMSC-based cell therapy using non-viral vectors has not been establ

285 Cell therapy was also found to improve liver glycogen st

286 Response to cell therapy was defined by changes in left ventricular

287 Cell therapy was not associated with severe adverse even

288 rd decreased liver fibrosis with endothelial cell therapy was observed.

289 Transendocardial CD133(+) cell therapy was safe.

290 After cell therapy, we found a temporary (15 weeks) decrease i

291 on in low-contamination applications such as cell therapies, where good manufacturing practice compat

292 fficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid tumors.

293 oint toward a future when antigen-specific T-cell therapies will play a central role in alloHSCT.

294 in future studies aimed at developing liver cell therapies with lab-made hepatocytes.

295 rvival significantly enhanced after adoptive cell therapy with agonist OX40 immunotherapy.

296 imaging-guided catheter-directed endothelial cell therapy with an intraportal technique for the treat

297 ory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable res

298 function in animal models of heart failure; cell therapy, with autologous bone marrow derived mononu

299 that a combination of alpha-4-1BB and CAR T-cell therapy would result in improved antitumor response

300 ration, and differentiation of cells in stem cell therapies, wound healing, and the treatment of canc